Albany, NY -- (SBWIRE) -- 07/25/2016 -- Non-invasive prenatal testing is increasingly being adopted by high-risk pregnant women for screening common fetal chromosomal aneuploidies such as Down syndrome (trisomy 21), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Turner syndrome (monosomy X). Non-invasiveness, accuracy, and safety are the major factors attributed to the popularity of these tests among gynecologists and expecting mothers compared to invasive tests such as chorionic villus sampling (CVS) and amniocentesis. MaterniT21 (now known as MaterniT21 PLUS) was the first NIPT launched in October 2011 by U.S.-based Sequenom, Inc. Since then, it has led the market, accounting for the largest share in terms of revenue as well as volume (number of tests performed in a year).

However, BGI's NIFTY is expected to outperform MaterniT21 PLUS in terms of volume in the global market by the end of 2014. Sequenom, Inc. is likely to maintain its leadership position in North America through 2022. Harmony, verifi, Panorama, informaSeq, VisibiliT, PrenaTest, and BambniTest are the other commercially available NIPTs for detecting chromosomal abnormalities.

Download Complete Healthcare Analytical Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=374

A new Transparency Market Research report states that the global non-invasive prenatal testing market was valued at US$0.53 bn in 2013 and is predicted to touch US$2.38 bn by 2022, by expanding at a strong 17.50% CAGR between 2014 and 2022. The title of the report is "Non-invasive Prenatal Testing (NIPT) Market - Global Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 - 2022."

Non-invasive prenatal testing (NIPT), also referred to as non-invasive prenatal diagnosis, is a method of screening employed for detecting specific types of chromosomal abnormalities that may take place in a developing fetus. These chromosomal abnormalities are Turner syndrome (monosomy X), Edwards syndrome (trisomy 18), Patau syndrome (trisomy 13), and Down syndrome (trisomy 21). This type of testing involves a blood test for assessing the fetal DNA within the maternal bloodstream. Along with diagnosing the probability of developing any chromosomal abnormalities in a fetus, this test is also utilized for determining the sex of the baby and rhesus (Rh) blood type. The conventionally utilized invasive prenatal genetic tests such as chorionic villus sampling (CVS) and amniocentesis involved the risk of miscarriage and hence are being substituted with NIPT.

As per the report, the non-invasive nature, safety, and accuracy are the prime factors boosting the demand for non-invasive prenatal testing amongst expecting mothers and gynecologists. In addition, the increasing occurrence rate of babies detected with Down syndrome is another factor fuelling the growth of the market for non-invasive prenatal testing. The rising shift toward having a child at an advanced age and no risk of miscarriage involved in the use of NIPT will also positively impact the development of the market. On the other hand, the presence of other kinds of testing and screening methods and the increasing count of regulatory guidelines globally may impede the growth of the market in the coming years.

Berry Genomics Co. Ltd., Laboratory Corporation of America Holdings, Illumina Inc., Sequenom Inc., LifeCodexx AG, Ariosa Diagnostics Inc., Natera Inc., and BGI Diagnostics, among others, are the chief players operating in the global non-invasive prenatal testing market.